Traders bought shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on weakness during trading on Tuesday. $133.25 million flowed into the stock on the tick-up and $109.53 million flowed out of the stock on the tick-down, for a money net flow of $23.72 million into the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 27th highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($3.87) for the day and closed at $368.65

REGN has been the topic of a number of research analyst reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Credit Suisse Group reaffirmed a “buy” rating and set a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. UBS Group lowered their target price on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, September 21st. Guggenheim reaffirmed a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Citigroup reaffirmed a “buy” rating and set a $480.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $471.11.

The stock has a market capitalization of $39,610.00, a P/E ratio of 33.48, a price-to-earnings-growth ratio of 1.45 and a beta of 1.52. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the business posted $3.13 EPS. equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 13.55 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in REGN. Harding Loevner LP grew its stake in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after acquiring an additional 3,131,966 shares in the last quarter. Janus Henderson Group PLC grew its stake in Regeneron Pharmaceuticals by 15,495.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after acquiring an additional 1,552,948 shares in the last quarter. FMR LLC grew its stake in Regeneron Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after acquiring an additional 416,192 shares in the last quarter. Old Mutual Global Investors UK Ltd. grew its stake in Regeneron Pharmaceuticals by 500,446.2% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after acquiring an additional 325,290 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 97.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 485,336 shares of the biopharmaceutical company’s stock valued at $238,368,000 after acquiring an additional 239,937 shares in the last quarter. 66.63% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2018/01/09/investors-buy-shares-of-regeneron-pharmaceuticals-regn-on-weakness.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.